Denali Therapeutics Q3 EPS $0.37 Beats $(0.59) Estimate, Sales $17.778M Beat $10.657M Estimate
Benzinga Newsdesk 1 day ago
NewsEarningsEarnings Beats
Denali Therapeutics (NASDAQ:DNLI) reported quarterly earnings of $0.37 per share which beat the analyst consensus estimate of $(0.59) by 162.71 percent. This is a 150 percent increase over losses of $(0.74) per share
Denali Therapeutics (NASDAQ:DNLI) reported quarterly earnings of $0.37 per share which beat the analyst consensus estimate of $(0.59) by 162.71 percent. This is a 150 percent increase over losses of $(0.74) per share from the same period last year. The company reported quarterly sales of $17.778 million which beat the analyst consensus estimate of $10.657 million by 66.83 percent.